These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2194133)

  • 1. Influence of thymopentin on antibody response, and monocyte and T cell function in hemodialysis patients who fail to respond to hepatitis B vaccination.
    Dumann H; Meuer SC; Renschin G; Köhler H
    Nephron; 1990; 55(2):136-40. PubMed ID: 2194133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymopentin as adjuvant therapy to hepatitis B vaccination in formerly non-or hyporesponding hemodialysis patients.
    Zàruba K; Grob PJ; Bolla K
    Surv Immunol Res; 1985; 4 Suppl 1():102-6. PubMed ID: 3898280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymopentin as adjuvant to hepatitis B vaccination. Results from three double-blind studies.
    Grob PJ; Binswanger U; Blumberg A; Gloor HJ; Hany A; Herwig W; Iselin H; Zàruba K; Bolla K
    Surv Immunol Res; 1985; 4 Suppl 1():107-15. PubMed ID: 3898281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Thymopentin as adjuvant therapy in the hepatitis B vaccination of non- or hyporesponsive subjects].
    Fuliano P; Fontana L; Bigolari M; Bovone U; Orengo G; Astengo F
    Minerva Med; 1990 May; 81(5):407-13. PubMed ID: 2198499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymopentin as adjuvant in non-responders or hyporesponders to hepatitis B vaccination.
    Záruba K; Rastorfer M; Grob PJ; Joller-Jemelka H; Bolla K
    Lancet; 1983 Nov; 2(8361):1245. PubMed ID: 6139582
    [No Abstract]   [Full Text] [Related]  

  • 6. Controlled trial of thymopentin in hemodialysis patients who fail to respond to hepatitis B vaccination.
    Donati D; Gastaldi L
    Nephron; 1988; 50(2):133-6. PubMed ID: 3065661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulation with thymopentin in humans.
    Bolla K; Duchateau J; Delespesse G; Servais G
    Int J Clin Pharmacol Res; 1984; 4(6):431-8. PubMed ID: 6398312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of immunomodulator thymopentin on impaired seroresponse to influenza vaccine in patients on haemodialysis.
    Beyer WE; Noordzij TC; Kramer P; Diderich PP; Op den Hoek CT; Janssen J; Masurel N; Weimar W
    Nephron; 1990; 54(4):296-301. PubMed ID: 2183079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymopentin administration and increase of sero-conversion after B-hepatitis vaccine in diabetic patients.
    Pagani S; Cruciani L; Chianelli M; Procaccini E; Pozzilli P
    Diabetes Res; 1989 Dec; 12(4):199-201. PubMed ID: 2534655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of immune response in aged humans through different administration modes of thymopentin.
    Duchateau J; Servais G; Vreyens R; Delespesse G; Bolla K
    Surv Immunol Res; 1985; 4 Suppl 1():94-101. PubMed ID: 3898299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Brief treatment with thymopentin as adjuvant in vaccination for hepatitis B: controlled study in patients on periodic hemodialysis].
    Palestini M; Messina A; Ciaraffo F; De Sanctis GM; Errera G; Corradini SG
    Riv Eur Sci Med Farmacol; 1990 Apr; 12(2):135-9. PubMed ID: 2080311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Stimulation of immunogenesis by neurotensin, pentagastrin and thymopentin and ways of its realization].
    Belokrylov GA; Molchanova IV; Popova OIa
    Biull Eksp Biol Med; 1989 Nov; 108(11):584-7. PubMed ID: 2699257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis: the adjuvant role of thymopentin on immunological response to hepatitis B virus vaccine in end-stage renal disease.
    Fabrizi F; Dixit V; Martin P
    Aliment Pharmacol Ther; 2006 Jun; 23(11):1559-66. PubMed ID: 16696803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a synthetic extract (thymopentin) on the immune system of lepromatous leprosy patients.
    Munno I; Pellegrino NM; Fumo G; Barbieri G; Polimeno G; de Filippis V; Jirillo E
    Cytobios; 1987; 52(210-211):167-73. PubMed ID: 3123147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B vaccination and interleukin 2 receptor expression in chronic renal failure.
    Dumann H; Meuer S; Meyer zum Büschenfelde KH; Köhler H
    Kidney Int; 1990 Dec; 38(6):1164-8. PubMed ID: 2150086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo enhancement of NK-cell activity by thymopentin.
    Hu C; Radelli L; Scorza R; Bonara P; Perego R; Fantuzzi G
    Int J Immunopharmacol; 1990; 12(2):193-7. PubMed ID: 2184134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo immunopotentiating activity of thymopentin in aging humans: increase of IL-2 production.
    Meroni PL; Barcellini W; Frasca D; Sguotti C; Borghi MO; De Bartolo G; Doria G; Zanussi C
    Clin Immunol Immunopathol; 1987 Feb; 42(2):151-9. PubMed ID: 3542319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulation with thymopentin: in vitro studies.
    Duchateau J; Bolla K
    Med Oncol Tumor Pharmacother; 1989; 6(1):19-23. PubMed ID: 2657246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of immunomodulators (thymopentine) in hepatitis B vaccine in elderly patients undergoing chronic hemodialysis.
    Melappioni M; Baldassari M; Baldini S; Radicioni R; Panichi N
    Nephron; 1992; 61(3):358-9. PubMed ID: 1386910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination.
    Evans TG; Schiff M; Graves B; Agosti J; Barritt ML; Garner D; Holley JL
    Clin Nephrol; 2000 Aug; 54(2):138-42. PubMed ID: 10968690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.